Continuous cell division is a hallmark of cancer, and the underlying mechanism is tumor
genomics instability. Cell cycle checkpoints are critical for enabling an orderly cell cycle and …

Introduction Poly (ADP-ribose) polymerase inhibitors (PARPis) are an exciting class of
agents that have shown efficacy, particularly for BRCA-mutant triple-negative breast cancer …

Abstract Purpose: The Wee1 kinase inhibitor adavosertib abrogates cell-cycle arrest,
leading to cell death. Prior testing of twice-daily adavosertib in patients with advanced solid …

The use of PARP inhibitors (PARPi) is growing widely as FDA approvals have shifted its use
from the recurrence setting to the frontline setting. In parallel, the population developing …

Introduction The anti-tumor activity of WEE1 inhibitors (WEE1i) in gynecological
malignancies has recently been demonstrated in clinical trials and its rationale is based on …

Background Adavosertib (AZD1775) is a first-in-class, selective, small-molecule inhibitor of
Wee1. Objective The safety, tolerability, pharmacokinetics, and efficacy of adavosertib …

Simple Summary The DNA damage response (DDR) is frequently altered in ovarian cancer
(OC), which can be exploited for therapeutic purposes. Moreover, targeting DDR signaling …

Small cell lung cancer (SCLC) is treated as a monolithic disease despite the evident intra-
and intertumoral heterogeneity. Non-specific DNA-damaging agents have remained the first …

Small cell lung cancer (SCLC) is a very aggressive, highly lethal, neuroendocrine tumor that
constitutes 15% of all lung cancer cases. It is characterized by its rapid disease progression …

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy. Most of the
patients of PDAC present at later stages of disease and have a five-year survival rate of less …